… accelerate dengue vaccine development and phase 3 vaccine efficacy trials in countries
where dengue is endemic. A protective tetravalent vaccine must be licensed soon if dengue is …

… Thereby, this pushes the demand for a dengue vaccine as a long-term protective approach.
… be the next vaccine to advance to the finish line in near future. Economic analysis on this …

… of ADE of dengue infections/disease. The revised understanding of dengue protective immunity
… the outcome of vaccine efficacy trials of the two dengue vaccines currently in phase III. …

… intensity of dengue vaccine … dengue vaccines have been tested in human clinical trials,
and a single candidate is now in phase III clinical trials. Different approaches in dengue vaccine …

… may consider a one-step approach where the whole procedure is done as a single intervention,
using the best RDT available, or a two-step approach where sampling, screening and …

… For most dengue vaccine approaches, the standard strategy has been to develop the four
monovalent candidates separately and evaluate them singly first and then in combination. As …

… In the late 1980’s new approaches to dengue vaccine development were attempted including
directed mutagenesis to attenuate DENV strains and development of chimeras splicing …

… of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine
… , including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus …

… any of the four serotypes of dengue viruses can cause disease. The development of a dengue
vaccine aims to provide … Various vaccine approaches used for the development of dengue …

… A variation of the genetic vaccination approach that does away with the virus vector relies
instead on naked plasmid DNA to deliver antigens to the immune system ( Table 3 ). The …